GSK3B and neuroblastoma: To corroborate the great potential of allosteric modulators in overcoming the great challenge in GSK-3β targeting, the effect of 33 and 34 on β-catenin localization was evaluated in two different human cell lines of glioblastoma and neuroblastoma, LN-18 and SH-SY5Y, respectively.